Mesoblast has long been one of the sharemarket's most polarising companies. Now it faces a momentous month awaiting results from trials of a potentially life-saving treatment for COVID-19.
The Melbourne-based biotech is also hopeful of a regulatory breakthrough in the US which could see its treatment for a life-threatening inflammatory condition in children approved by the US Food and Drug Administration (FDA).
Loading...
Tom Richardson was a journalist at The Australian Financial Review
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
